Resolvin D1 as a novel anti-inflammatory marker in manic, depressive and euthymic states of bipolar disorder

Kendirlioglu, Burcu Kok; Ozpercin, Pelin Unalan; Oksuz, Ozge Yuksel; Sözen, Şule; Cihnioğlu, Refik; Kalelioğlu, Tevfik; İlnem, Mehmet Cem; Karamustafalıoğlu, Nesrin

doi:10.1080/08039488.2019.1673480

Cited by 14 publications

(13 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As a result, the decrease of RvD1 levels in Alzheimer's and Parkinson's disease patient's brain could contribute to the disease development and progression. Conversely, an increased anti-inflammatory RvD1 activity has been reported in maniac and depressive patients, suggesting that RvD1 may serve to improve inflammatory imbalance [154].…”

Section: In Humansmentioning

confidence: 99%

n-3 Polyunsaturated Fatty Acids and Their Derivates Reduce Neuroinflammation during Aging

et al. 2020

View full text Add to dashboard Cite

Aging is associated to cognitive decline, which can lead to loss of life quality, personal suffering, and ultimately neurodegenerative diseases. Neuroinflammation is one of the mechanisms explaining the loss of cognitive functions. Indeed, aging is associated to the activation of inflammatory signaling pathways, which can be targeted by specific nutrients with anti-inflammatory effects. Dietary n-3 polyunsaturated fatty acids (PUFAs) are particularly attractive as they are present in the brain, possess immunomodulatory properties, and are precursors of lipid derivates named specialized pro-resolving mediators (SPM). SPMs are crucially involved in the resolution of inflammation that is modified during aging, resulting in chronic inflammation. In this review, we first examine the effect of aging on neuroinflammation and then evaluate the potential beneficial effect of n-3 PUFA as precursors of bioactive derivates, particularly during aging, on the resolution of inflammation. Lastly, we highlight evidence supporting a role of n-3 PUFA during aging.

show abstract

Section: In Humansmentioning

confidence: 99%

n-3 Polyunsaturated Fatty Acids and Their Derivates Reduce Neuroinflammation during Aging

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The potential antidepressant effect of RvD1 has been evaluated in a limited number of studies. A recent study showed that patients with mania or depression had higher serum levels of RvD1, 11 implying the involvement of RvD1 in the pathophysiology of depression. In accordance, infusion of RvD1 into the medial prefrontal cortex or dentate gyrus of the hippocampus provoked significant antidepressant effects via activation of ALX/FPR2.…”

Section: Depressionmentioning

confidence: 99%

“…8,9 Many beneficial effects of fish oil supplements are associated with the production of these metabolites. On the other hand, changes in the plasma SPMs levels have been described in several neurological diseases including ischemic stroke, 10 depression, 11 Alzheimer's and Parkinson's diseases (AD and PD), 12 amyotrophic lateral sclerosis (ALS), 13 and multiple sclerosis. 14,15 Resolvins have been reported with significant immunoresolvent potentials.…”

Section: Introductionmentioning

confidence: 99%

Resolvin D1: A key endogenous inhibitor of neuroinflammation

2022

View full text Add to dashboard Cite

After the initiation of inflammation, a series of processes start to resolve the inflammation. A group of endogenous lipid mediators, namely specialized pro‐resolving lipid mediators is at the top list of inflammation resolution. Resolvin D1 (RvD1), is one of the lipid mediators with significant anti‐inflammatory properties. It is produced from docosahexaenoic acid (omega‐3 polyunsaturated fatty acid) in the body. In this article, we aimed to review the most recent findings concerning the pharmacological effects of RvD1 in the central nervous system with a focus on major neurological diseases and dysfunctions. A literature review of the past studies demonstrated that RvD1 plasma level changes during mania, depression, and Parkinson's disease. Furthermore, RVD1 and its epimer, aspirin‐triggered RvD1 (AT‐RvD1), have significant therapeutic effects on experimental models of ischemic and traumatic brain injuries, memory dysfunction, pain, depression, amyotrophic lateral sclerosis, and Alzheimer's and Parkinson's diseases. Interestingly, the beneficial effects of RvD1 and AT‐RvD1 were mostly induced at nanomolar and micromolar concentrations implying the significant potency of these lipid mediators in treating diseases with inflammation.

show abstract

“…Simultaneously some clinical studies suggest that RvD1 may be an attractive marker in manic, depressive and euthymic states of bipolar disorders. In fact, the levels of RvD1 were enhanced in manic and depressive states in comparison with the appropriate control groups [ 112 ]. Since RvD1 level correlated with an increase in the c-reactive protein, it is possible that RvD1 concentration should also be indicative of the presence of a subclinical inflammation, especially in the course of acute episodes to compensate for the inflammatory response.…”

Section: Fpr2 Agonists In the Course Of The Resolution Of Inflammationmentioning

confidence: 99%

Formyl peptide receptor 2, as an important target for ligands triggering the inflammatory response regulation: a link to brain pathology

et al. 2021

View full text Add to dashboard Cite

Formyl peptide receptors (FPRs) belong to the family of seven-transmembrane G protein-coupled receptors. Among them, FPR2 is a low affinity receptor for N-formyl peptides and is considered the most promiscuous member of FPRs. FPR2 is able to recognize a broad variety of endogenous or exogenous ligands, ranging from lipid to proteins and peptides, including non-formylated peptides. Due to this property FPR2 has the ability to modulate both pro- and anti-inflammatory response, depending on the nature of the bound agonist and on the different recognition sites of the receptor. Thus, FPR2 takes part not only in the proinflammatory response but also in the resolution of inflammation (RoI) processes. Recent data have indicated that the malfunction of RoI may be the background for some central nervous system (CNS) disorders. Therefore, much interest is focused on endogenous molecules called specialized pro-resolving mediators (SPMs), as well as on new synthetic FPR2 agonists, which kick-start the resolution of inflammation (RoI) and modulate its course. Here, we shed some light on the general characteristics of the FPR family in humans and in the experimental animals. Moreover, we present a guide to understanding the “double faced” action of FPR2 activation in the context of immune-related diseases of the CNS.

show abstract

Resolvin D1 as a novel anti-inflammatory marker in manic, depressive and euthymic states of bipolar disorder

Cited by 14 publications

References 25 publications

n-3 Polyunsaturated Fatty Acids and Their Derivates Reduce Neuroinflammation during Aging

n-3 Polyunsaturated Fatty Acids and Their Derivates Reduce Neuroinflammation during Aging

Resolvin D1: A key endogenous inhibitor of neuroinflammation

Formyl peptide receptor 2, as an important target for ligands triggering the inflammatory response regulation: a link to brain pathology

Contact Info

Product

Resources

About